A live results discussion is set for Nov. 3, after QuidelOrtho reports earnings.

QuidelOrtho (QDEL) will report Q3 2026 earnings on Nov. 3, followed by a conference call and webcast at 5:00 p.m. ET. The company is a global diagnostics provider, offering solutions for clinical chemistry, immunoassay, and molecular testing. Interested parties can access the live webcast on the company's Investor Relations page.

Original reporting
Published Oct 20, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QDEL
Neutral
medium confidence
Mentioned
$QDEL
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$QDELNeutralLow
01

Why it matters

The upcoming earnings call provides a timing cue for traders to position ahead of potential price movement.

02

Market read

The announcement signals the date of the next earnings release, a standard catalyst for short‑term trading activity.

03

What to watch

Potential impact of recent FDA approvals or reimbursement changes not mentioned in the release.

Relevance 4/10Novelty 2/10Timing: Nov 3 earnings release

Background

QuidelOrtho is a Nasdaq‑listed provider of diagnostic solutions. The company routinely reports quarterly results.

Company-level read

Ticker impact

$QDELNeutralMedium confidence
Context

QuidelOrtho will report its Q3 2026 earnings on Nov 3 and host a live webcast to discuss the results.

Expected impact

potential price swing after the earnings announcement, direction depends on results versus expectations

Evidence & confidence

No financial figures are disclosed yet; the market will react once the results are posted.

Market effects

Diagnostic testing sector may see broader movement based on QuidelOrtho's performance.

U.S. healthcare equities could be influenced by the results.

Limited to investors tracking U.S. med‑tech stocks.

Counterpoint

If the market has already priced in strong growth, the earnings could disappoint and trigger a sell‑off.

Key entities

  • QuidelOrtho Corporation

    Diagnostic solutions provider (NASDAQ: QDEL).

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.